NEW YORK (TheStreet) -- CHANGE IN RATINGS
was downgraded at BMO Capital to market perform from outperform. Valuation call, based on a $42 price target, BMO Capital said.
was upgraded to hold at TheStreet Ratings.
was downgraded at Goldman Sachs to neutral from buy. Valuation call, based on a $40 price target, Goldman said.
was downgraded to hold at TheStreet Ratings.
was upgraded at Oppenheimer to outperform from perform. $72 price target. Company is seeing higher end-market demand and has better potential for revenue synergy, Oppenheimer said.
was upgraded at Canaccord Genuity to buy from hold. $67 price target. Marketplaces and PayPal can continue to drive growth, Canaccord said. $67 price target.
was downgraded at Morgan Stanley to equal-weight from overweight. $49 price target. Company lacks near-term catalysts, Morgan Stanley said.
was downgraded at JMP Securities to market perform from outperform. Company will no longer pursue the Haswell architecture, JMP Securities said.
was upgraded at Credit Suisse to outperform from neutral. $36 price target. Company should see higher cable growth and margin expansion, Credit Suisse said.
was upgraded at Canaccord Genuity to buy from hold. $7 price target. Company can gain share in the LTE smartphone market, Canaccord Genuity said.
was downgraded at MKM Partners to neutral from buy. Company lacks near-term catalysts, MKM said.
was downgraded at Lazard Capital Markets to neutral from buy. Valuation call, based on a $36 price target, Lazard Capital Markets said.
was downgraded at Pivotal Research Group to hold from buy. Valuation call, based on a $26 price target, Pivotal Research said.
STOCK COMMENTS/EPS CHANGES
numbers were cut at UBS. Shares are now seen reaching $120. Estimates were also lowerd on FDA warning letter and EU updates, UBS said. Buy rating.
estimates were raised at UBS through 2015. Quarter comforted by margin, lean channel, enterprise prospects, and guidance, UBS said. Neutral rating and $13 price target.
numbers were raised at UBS. Shares are now seen reaching $200. Estimates were also raised on lower risk, BG-12 pricing, UBS said. Neutral rating.
Cliffs Natural Resources
was added to the Analyst Focus List at J.P. Morgan. $40 price target. Capacity fears have been overblown, J.P. Morgans said.
estimates were lowered at UBS through 2015. Preliminary proxy offers go private rationale, UBS said. Neutral rating and $13.65 price target.
estimates, price target were raised at J.P. Morgan. Shares are now seen reaching $64. Estimates were also increased, following the company's upbeat investor meeting, J.P. Morgan said. Overweight rating.
estimates, price target were increased at Drexel Hamilton. Estimates were raised through 2015. Company has better sales and margin visibility, Drexel Hamilton said. Buy rating and new $85 price target.
Johnson & Johnson
price target was raised at UBS to $89. FDA approves Invokana, UBS said. Buy rating.
price target was raised at UBS to $25. Claims trend comparisons get easier beginning in the second quarter of 2013. Neutral rating.
was cut from the Conviction Buy List at Goldman Sachs. $19 price target. Company lacks near-term catalysts, Goldman Sachs said.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.